B3GALT5 and neoplasm: The overall survival (OS) correlated with the higher AJCC cancer stages III–IV (HR = 2.81, P = 2.5E−04), and higher expression of B3GALT5 in adjacent non-tumor part (HR = 2.63, P = 4.7E−03).